FY2025 · ended Dec 31, 2025 · Revenue $593,000, -13.2% YoY · Filed Feb 24, 2026
Cardiff Oncology, Inc. (CRDF) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $593,000 and a net loss of $45.9 million. Free cash flow was -$38.0 million. As of Jun 30, 2026 it held $43.7 million in cash and investments and $457,000 in total debt.
Revenue (TTM)
$508,000
-6.8% vs year-ago TTM
Net income (TTM)
$-40.05M
+21.5% vs year-ago TTM
Operating cash flow (TTM)
$-40.85M
+2.4% vs year-ago TTM
Free cash flow (TTM)
$-40.92M
+2.3% vs year-ago TTM
EPS (TTM)
$-0.59
+32.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
68.36M
+2.8% vs prior year
Net cash
$43.20M
as of Jun 30, 2026
Operating margin
-8320.1%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRDF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1213037
- Former names
- Trovagene, Inc. (until May 7, 2020); TrovaGene Inc. (until Mar 4, 2013); XENOMICS INC (until Jun 3, 2009); USED KAR PARTS INC (until Jun 30, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M |
| Net income | -$45.9M | -$45.4M | -$41.4M | -$38.7M | -$28.3M |
| Diluted EPS | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 |
| Operating cash flow | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M |
| Free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | -$23.2M |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M |
| Stockholders' equity | $45.4M | $82.9M | $69.7M | $106.3M | $140.4M |
| Cash and investments | $67.2M | $98.0M | $101.7M | $110.3M | $174.1M |
| Total debt | $832,000 | $1.5M | $2.1M | $2.7M | $3.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 27, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 16, 2026 | Jul 14, 2026 |
All 1001 Cardiff Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.